


PHARMACEUTICAL 2017

Assertio Therapeutics Inc Rank 37 of 313





PHARMACEUTICAL 2017



Assertio Therapeutics Inc Rank 37 of 313

The relative strengths and weaknesses of Assertio Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Assertio Therapeutics Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 269% points. The greatest weakness of Assertio Therapeutics Inc is the variable Other Expenses, reducing the Economic Capital Ratio by 60% points.

The company's Economic Capital Ratio, given in the ranking table, is 102%, being 518% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	306,204
Cost of Goods Sold	0
Intangible Assets	902,149
Liabilities, Current	227,242
Liabilities, Non-Current	0
Other Assets	1,458
Other Compr. Net Income	35
Other Expenses	218,477
Other Liabilities	0
Other Net Income	-89,011
Property and Equipment	15,526
Research and Development	32,631
Revenues	455,897
Selling, General and Administrative Expense	204,498

Output Variable	Value in 1000 USD
Assets	1,225,337
Liabilities	227,242
Expenses	455,606
Stockholders Equity	998,095
Net Income	-88,720
Comprehensive Net Income	-88,702
Economic Capital Ratio	102%